Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours.

Song E, Mao T, Dong H, Boisserand LSB, Antila S, Bosenberg M, Alitalo K, Thomas JL, Iwasaki A.

Nature. 2020 Jan 15. doi: 10.1038/s41586-019-1912-x. [Epub ahead of print]

PMID:
31942068
2.

Siah2 control of T-regulatory cells limits anti-tumor immunity.

Scortegagna M, Hockemeyer K, Dolgalev I, Poźniak J, Rambow F, Li Y, Feng Y, Tinoco R, Otero DC, Zhang T, Brown K, Bosenberg M, Bradley LM, Marine JC, Aifantis I, Ronai ZA.

Nat Commun. 2020 Jan 7;11(1):99. doi: 10.1038/s41467-019-13826-7.

3.

Tumor-Targeted, Cytoplasmic Delivery of Large, Polar Molecules Using a pH-Low Insertion Peptide.

Svoronos AA, Bahal R, Pereira MC, Barrera FN, Deacon JC, Bosenberg M, DiMaio D, Glazer PM, Engelman DM.

Mol Pharm. 2020 Jan 13. doi: 10.1021/acs.molpharmaceut.9b00883. [Epub ahead of print]

PMID:
31855437
4.

PLEKHA5 regulates tumor growth in metastatic melanoma.

Zhang H, Zhu H, Deng G, Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg MW, Kluger HM, Jilaveanu LB.

Cancer. 2019 Nov 26. doi: 10.1002/cncr.32611. [Epub ahead of print]

PMID:
31769872
5.

Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses.

Jiang X, Muthusamy V, Fedorova O, Kong Y, Kim DJ, Bosenberg M, Pyle AM, Iwasaki A.

J Exp Med. 2019 Dec 2;216(12):2854-2868. doi: 10.1084/jem.20190801. Epub 2019 Oct 10.

6.

Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence.

Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits E, Baruch EN, Tripple V, Arama-Chayoth M, Greenberg E, Shenoy A, Ayasun R, Knafo N, Xu S, Anafi L, Yanovich-Arad G, Barnabas GD, Ashkenazi S, Besser MJ, Schachter J, Bosenberg M, Shadel GS, Barshack I, Kaech SM, Markel G, Geiger T.

Cell. 2019 Sep 19;179(1):236-250.e18. doi: 10.1016/j.cell.2019.08.012. Epub 2019 Sep 5.

PMID:
31495571
7.

Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression.

Etzerodt A, Tsalkitzi K, Maniecki M, Damsky W, Delfini M, Baudoin E, Moulin M, Bosenberg M, Graversen JH, Auphan-Anezin N, Moestrup SK, Lawrence T.

J Exp Med. 2019 Oct 7;216(10):2394-2411. doi: 10.1084/jem.20182124. Epub 2019 Aug 2.

PMID:
31375534
8.

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors.

Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM.

J Immunother Cancer. 2019 Jun 14;7(1):153. doi: 10.1186/s40425-019-0613-1.

9.

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells.

Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL.

J Vis Exp. 2019 May 17;(147). doi: 10.3791/59370.

PMID:
31157760
10.

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, Bosenberg MW, Engelhard VH, Slingluff CL Jr.

Cancer Immunol Immunother. 2019 Jul;68(7):1121-1132. doi: 10.1007/s00262-019-02345-5. Epub 2019 May 27.

PMID:
31134297
11.

Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5-/- mice.

Li Y, Tinoco R, Elmén L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y, Khateb A, Frederick DT, Ashkenazi SK, Kim H, Perez EG, Day CP, Segura Muñoz RS, Schmaltz R, Yooseph S, Tam MA, Zhang T, Avitan-Hersh E, Tzur L, Roizman S, Boyango I, Bar-Sela G, Orian A, Kaufman RJ, Bosenberg M, Goding CR, Baaten B, Levesque MP, Dummer R, Brown K, Merlino G, Ruppin E, Flaherty K, Ramer-Tait A, Long T, Peterson SN, Bradley LM, Ronai ZA.

Nat Commun. 2019 Apr 2;10(1):1492. doi: 10.1038/s41467-019-09525-y.

12.

Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting.

Sullivan MR, Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, Meeth K, Muir A, Darnell AM, Bosenberg MW, Lewis CA, Vander Heiden MG.

Cell Metab. 2019 Jun 4;29(6):1410-1421.e4. doi: 10.1016/j.cmet.2019.02.015. Epub 2019 Mar 21.

PMID:
30905671
13.

Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo.

Codina A, Renauer PA, Wang G, Chow RD, Park JJ, Ye H, Zhang K, Dong MB, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, Bosenberg M, Rinehart J, Fan R, Chen S.

Cell Syst. 2019 Feb 27;8(2):136-151.e7. doi: 10.1016/j.cels.2019.01.004. Epub 2019 Feb 20.

PMID:
30797773
14.

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.

Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Chen YA, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM.

Pigment Cell Melanoma Res. 2019 May;32(3):458-469. doi: 10.1111/pcmr.12771. Epub 2019 Feb 19.

PMID:
30712316
15.

Pathology of spontaneous and immunotherapy-induced tumor regression in a murine model of melanoma.

Blenman KRM, Wang J, Cowper S, Bosenberg M.

Pigment Cell Melanoma Res. 2019 May;32(3):448-457. doi: 10.1111/pcmr.12769. Epub 2019 Feb 27.

PMID:
30702217
16.

Single-Cell Analysis Reveals a Hair Follicle Dermal Niche Molecular Differentiation Trajectory that Begins Prior to Morphogenesis.

Gupta K, Levinsohn J, Linderman G, Chen D, Sun TY, Dong D, Taketo MM, Bosenberg M, Kluger Y, Choate K, Myung P.

Dev Cell. 2019 Jan 7;48(1):17-31.e6. doi: 10.1016/j.devcel.2018.11.032. Epub 2018 Dec 27.

17.

KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations.

Liu X, Zhang SM, McGeary MK, Krykbaeva I, Lai L, Jansen DJ, Kales SC, Simeonov A, Hall MD, Kelly DP, Bosenberg MW, Yan Q.

Mol Cancer Ther. 2019 Mar;18(3):706-717. doi: 10.1158/1535-7163.MCT-18-0395. Epub 2018 Dec 6.

PMID:
30523048
18.

Author Correction: Autophagy maintains tumour growth through circulating arginine.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD, White E.

Nature. 2019 Jan;565(7737):E3. doi: 10.1038/s41586-018-0815-6.

PMID:
30523330
19.

Immune Cell and Cell Cluster Phenotyping, Quantitation, and Visualization Using In Silico Multiplexed Images and Tissue Cytometry.

Blenman KRM, Bosenberg MW.

Cytometry A. 2019 Apr;95(4):399-410. doi: 10.1002/cyto.a.23668. Epub 2018 Nov 23.

PMID:
30468565
20.

scFTD-seq: freeze-thaw lysis based, portable approach toward highly distributed single-cell 3' mRNA profiling.

Dura B, Choi JY, Zhang K, Damsky W, Thakral D, Bosenberg M, Craft J, Fan R.

Nucleic Acids Res. 2019 Feb 20;47(3):e16. doi: 10.1093/nar/gky1173.

21.

Autophagy maintains tumour growth through circulating arginine.

Poillet-Perez L, Xie X, Zhan L, Yang Y, Sharp DW, Hu ZS, Su X, Maganti A, Jiang C, Lu W, Zheng H, Bosenberg MW, Mehnert JM, Guo JY, Lattime E, Rabinowitz JD, White E.

Nature. 2018 Nov;563(7732):569-573. doi: 10.1038/s41586-018-0697-7. Epub 2018 Nov 14. Erratum in: Nature. 2018 Dec 6;:.

22.

PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.

Micevic G, Thakral D, McGeary M, Bosenberg MW.

Pigment Cell Melanoma Res. 2019 May;32(3):435-440. doi: 10.1111/pcmr.12745. Epub 2018 Nov 22.

PMID:
30343532
23.

Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.

Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW.

Pigment Cell Melanoma Res. 2019 Mar;32(2):292-302. doi: 10.1111/pcmr.12742. Epub 2018 Oct 22.

PMID:
30281931
24.

Frontiers in pigment cell and melanoma research.

Filipp FV, Birlea S, Bosenberg MW, Brash D, Cassidy PB, Chen S, D'Orazio JA, Fujita M, Goh BK, Herlyn M, Indra AK, Larue L, Leachman SA, Le Poole C, Liu-Smith F, Manga P, Montoliu L, Norris DA, Shellman Y, Smalley KSM, Spritz RA, Sturm RA, Swetter SM, Terzian T, Wakamatsu K, Weber JS, Box NF.

Pigment Cell Melanoma Res. 2018 Nov;31(6):728-735. doi: 10.1111/pcmr.12728. Epub 2018 Oct 3.

25.

Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity.

Ventura A, Vassall A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL.

Cancer Res. 2018 Jul 15;78(14):4045-4058. doi: 10.1158/0008-5472.CAN-18-0171. Epub 2018 May 15.

26.

Genetics of metastasis: melanoma and other cancers.

Turner N, Ware O, Bosenberg M.

Clin Exp Metastasis. 2018 Aug;35(5-6):379-391. doi: 10.1007/s10585-018-9893-y. Epub 2018 May 2. Review.

PMID:
29722002
27.

Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.

Perry CJ, Muñoz-Rojas AR, Meeth KM, Kellman LN, Amezquita RA, Thakral D, Du VY, Wang JX, Damsky W, Kuhlmann AL, Sher JW, Bosenberg M, Miller-Jensen K, Kaech SM.

J Exp Med. 2018 Mar 5;215(3):877-893. doi: 10.1084/jem.20171435. Epub 2018 Feb 7.

28.

DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation.

Xiao Q, Wu J, Wang WJ, Chen S, Zheng Y, Yu X, Meeth K, Sahraei M, Bothwell ALM, Chen L, Bosenberg M, Chen J, Sexl V, Sun L, Li L, Tang W, Wu D.

Nat Med. 2018 Mar;24(3):262-270. doi: 10.1038/nm.4496. Epub 2018 Feb 12.

29.

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW.

J Immunother Cancer. 2017 Sep 19;5(1):77. doi: 10.1186/s40425-017-0278-6.

30.

The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression.

Pan W, Zhu S, Qu K, Meeth K, Cheng J, He K, Ma H, Liao Y, Wen X, Roden C, Tobiasova Z, Wei Z, Zhao J, Liu J, Zheng J, Guo B, Khan SA, Bosenberg M, Flavell RA, Lu J.

Immunity. 2017 Aug 15;47(2):284-297.e5. doi: 10.1016/j.immuni.2017.07.020.

31.

Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.

Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):E6157-E6165. doi: 10.1073/pnas.1700363114. Epub 2017 Jul 14.

32.

Melanocytic nevi and melanoma: unraveling a complex relationship.

Damsky WE, Bosenberg M.

Oncogene. 2017 Oct 19;36(42):5771-5792. doi: 10.1038/onc.2017.189. Epub 2017 Jun 12. Review.

33.

p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.

Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW.

J Invest Dermatol. 2017 Oct;137(10):2187-2196. doi: 10.1016/j.jid.2016.12.033. Epub 2017 Jun 7.

34.

Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities.

Micevic G, Theodosakis N, Bosenberg M.

Clin Epigenetics. 2017 Apr 4;9:34. doi: 10.1186/s13148-017-0332-8. eCollection 2017. Review.

35.

UV-induced somatic mutations elicit a functional T cell response in the YUMMER1.7 mouse melanoma model.

Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micevic G, Kaech S, Blenman K, Bosenberg M.

Pigment Cell Melanoma Res. 2017 Jul;30(4):428-435. doi: 10.1111/pcmr.12591. Epub 2017 Jun 8.

36.

Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas.

Lazova R, Pornputtapong N, Halaban R, Bosenberg M, Bai Y, Chai H, Krauthammer M.

Mod Pathol. 2017 May;30(5):640-649. doi: 10.1038/modpathol.2016.237. Epub 2017 Feb 10.

37.

A Computational Approach for Identifying Synergistic Drug Combinations.

Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O.

PLoS Comput Biol. 2017 Jan 13;13(1):e1005308. doi: 10.1371/journal.pcbi.1005308. eCollection 2017 Jan.

38.

Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.

Micevic G, Theodosakis N, Taube JM, Bosenberg MW, Rodić N.

Melanoma Res. 2017 Apr;27(2):85-96. doi: 10.1097/CMR.0000000000000315.

39.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

40.

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.

Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Ribas A.

Cancer Immunol Res. 2016 Oct;4(10):845-857. Epub 2016 Sep 2.

41.

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN.

JAMA Dermatol. 2016 Oct 1;152(10):1128-1136. doi: 10.1001/jamadermatol.2016.2226.

42.

Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance.

Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT.

Nature. 2016 Sep 8;537(7619):254. doi: 10.1038/nature18939. Epub 2016 Jul 6. No abstract available.

PMID:
27383789
43.

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.

Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, Swain SL, Bradley LM.

Immunity. 2016 Jun 21;44(6):1470. doi: 10.1016/j.immuni.2016.05.011. No abstract available.

44.

The YUMM lines: a series of congenic mouse melanoma cell lines with defined genetic alterations.

Meeth K, Wang JX, Micevic G, Damsky W, Bosenberg MW.

Pigment Cell Melanoma Res. 2016 Sep;29(5):590-7. doi: 10.1111/pcmr.12498. Epub 2016 Aug 3.

45.

Keratoacanthoma Shares Driver Mutations with Cutaneous Squamous Cell Carcinoma.

Lim YH, Fisher JM, Bosenberg MW, Choate KA, Ko CJ.

J Invest Dermatol. 2016 Aug;136(8):1737-1741. doi: 10.1016/j.jid.2016.04.002. Epub 2016 Jun 7. No abstract available.

46.

Cell and Tissue Display: An Alternative Multipurpose Tool for Microscopy.

Theodosakis N, Micevic G, Bosenberg MW, Rodić N.

J Histochem Cytochem. 2016 Jul;64(7):403-11. doi: 10.1369/0022155416651065. Epub 2016 Jun 7.

47.

Intratumoral multinucleated giant cells are not a prognostic pathologic feature in cutaneous melanoma.

Srisuttiyakorn C, Bulloch K, Rodic N, Bosenberg M, Ariyan S, Narayan D, Gould Rothberg BE, Galan A.

J Cutan Pathol. 2016 Oct;43(10):821-9. doi: 10.1111/cup.12750. Epub 2016 Jun 30.

PMID:
27246995
48.

A Transcriptionally Inactive ATF2 Variant Drives Melanomagenesis.

Claps G, Cheli Y, Zhang T, Scortegagna M, Lau E, Kim H, Qi J, Li JL, James B, Dzung A, Levesque MP, Dummer R, Hayward NK, Bosenberg M, Brown KM, Ronai ZA.

Cell Rep. 2016 May 31;15(9):1884-92. doi: 10.1016/j.celrep.2016.04.072. Epub 2016 May 19.

49.

PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.

Tinoco R, Carrette F, Barraza ML, Otero DC, Magaña J, Bosenberg MW, Swain SL, Bradley LM.

Immunity. 2016 May 17;44(5):1190-203. doi: 10.1016/j.immuni.2016.04.015.

50.

Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.

Ngiow SF, Meeth KM, Stannard K, Barkauskas DS, Bollag G, Bosenberg M, Smyth MJ.

Oncoimmunology. 2015 Dec 10;5(3):e1089381. eCollection 2016 Mar.

Supplemental Content

Loading ...
Support Center